BioSpace News Archive

PharmaLogic Holdings Corp. (“PharmaLogic” or “the Company”) today announces the signature of a Master Services Agreement with Viewpoint Molecular Targeting, Inc., a wholly-owned subsidiary of Perspective Therapeutics, Inc. (“Perspective”) (NYSE AMERICAN: CATX), for the development and production of theranostic candidates VMT-01 and VMT-α-NET.

Adamis Pharmaceuticals Corporation announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 16,500,000 shares of its common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, together with warrants to purchase up to 48,000,000 shares of common stock, at a combined purchase price of $0.125 per share and accompanying warrants, pursuant to a registered direct offering.

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced it does not have direct exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank.

Biocoat Incorporated, a specialty manufacturer of hydrophilic biomaterial coatings, coating services, and coating equipment for medical devices, today announced that its HYDAK® UV coating is now being used on two medical devices that have been awarded FDA 510(k) clearance status.

Mirum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved a reduction in age from one year to three months for LIVMARLI® oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome.

Scientists from Korea have developed a new biosensor that uses fluorescence resonance energy transfer (FRET) to detect DNA double-strand breaks in living specimens in real time.

Switch Therapeutics today announced its launch following $52 million of financing.

Ainos, Inc. today announced that it has signed a Memorandum of Understanding with Merdury Biopharmaceutical Corp., a Taipei Exchange Emerging Stock Board listed company (TPEx: Code 6932) (“Merdury”), to jointly explore and develop a strategic business relationship.

Alterity Therapeutics today announced that the composition of matter patent previously allowed by the United States Patent and Trademark Office (USPTO) has now been granted.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product candidates from its ophthalmology program.